Key result
Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
Why the study?
Does warfarin treatment reduce markers of thrombogenesis in patients with chronic atrial fibrillation?
Does warfarin treatment reduce markers of thrombogenesis in patients with chronic atrial fibrillation?
Warfarin treatment normalizes elevated D-dimer levels in patients with chronic atrial fibrillation, suggesting its utility as a marker for assessing reduction in thrombotic risk.
Answers are grounded in this paper and cite their sources.
D-dimer normalization with warfarin may indicate reduced thrombotic risk in chronic AF; leaves open its value as a biomarker pending prospective validation.
Increased median plasma fibrinogen and vWF levels were found in patients with chronic atrial fibrillation. Plasma D-dimer levels were also increased in patients with chronic atrial fibrillation not receiving warfarin, suggesting increased intravascular thrombogenesis in such patients. Introduction of warfarin normalised circulating fibrin D- dimer levels, suggesting that warfarin treatment was effective in preventing excessive fibrin turnover, consistent with the antithrombotic effects of warfarin. These results suggest three possible thrombotic markers to assess patients with atrial fibrillation who are at high risk of thrombogenesis; D-dimer also merits assessment as a measure of reduction in thrombotic risk in patients receiving warfarin.
No takes yet. Share an insight, caveat, or question.
Lip et al. (1995) studied this question. Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
Synapse has enriched 10 related papers. Consider them for comparative context: